USANA Health Sciences Inc. - Q1 2009 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 4, 2009. USANA Health Sciences, Inc. is a direct-selling company that develops, manufactures, and distributes nutritional and personal care products globally through a network of independent distributors ("Associates"). The company operates in North America and the Asia Pacific region, with significant manufacturing concentration in the United States.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 (Restated) |
|---|---|---|
| Net Sales | $97.3 million | $101.6 million |
| Gross Profit | $77.5 million (79.6% margin) | $80.1 million (78.8% margin) |
| Net Earnings | $6.6 million | $7.3 million |
| Diluted EPS | $0.43 | $0.44 |
| Cash and Equivalents | $9.7 million | $17.6 million (end of Q1 2008) |
| Operating Cash Flow | ($1.3 million) used | $9.1 million provided |
| Line of Credit Outstanding | $33.9 million | $35.0 million (approx. based on activity) |
Note: Q1 2008 figures have been restated to correct errors related to income taxes and stock option accounting.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 4.2% year-over-year. Management attributes approximately $10.4 million of this decline to the strengthening of the U.S. dollar against foreign currencies. Excluding currency impacts, sales in most markets increased.
- Profitability: Net earnings decreased 8.9%. While gross margin improved to 79.6% due to lower freight costs, this was offset by higher Associate incentive expenses (43.1% of sales vs. 40.7% prior year) and lower sales volume.
- Cash Flow Reversal: Operating cash flow turned negative ($1.3 million used) compared to a positive $9.1 million in the prior year. This was driven by unusual cash payments of $7.0 million for an arbitration award and $1.3 million for tax payments related to an IRS audit, alongside increased inventory levels.
- Customer Base: Active Associates increased 12.2% to 184,000, while Active Preferred Customers decreased 11.7% to 68,000, attributed to deteriorating global economic conditions.
Outlook, Risks, and Management Commentary
- Currency Risk: Management warns that the strengthening U.S. dollar will likely have a significant negative effect on net sales and operating cash flows for the remainder of 2009. The company currently has no currency exchange contracts in place.
- Liquidity Strategy: To accommodate unusual cash needs in 2009, the company may delay capital projects and reduce or eliminate share repurchases. No shares were repurchased in Q1 2009.
- Debt Covenants: The company maintains a $40 million credit facility with Bank of America. As of April 4, 2009, the company was in compliance with covenants requiring a rolling four-quarter EBITDA of at least $50 million and a debt-to-EBITDA ratio of 2.5 to 1.0.
- Restatement Impact: Historical financial statements for 2007 and 2008 were restated due to IRS audit settlements regarding Section 162(m) deductions and stock option treatment, resulting in increased tax liabilities and compensation expenses.
Investor Verification Checklist
- Currency Sensitivity: Verify the specific impact of the strengthening U.S. dollar on the Asia Pacific and Canadian markets, which represent over 60% of sales.
- Cash Burn Rate: Monitor the sustainability of negative operating cash flow given the $33.9 million draw on the line of credit and the $10.4 million remaining share repurchase authorization.
- Associate Retention: Assess whether the 12.2% growth in Associates can offset the 11.7% decline in Preferred Customers to drive future revenue growth.
- Debt Compliance: Confirm continued compliance with the EBITDA and debt coverage covenants in the Bank of America credit agreement.
- Inventory Levels: Review the increase in inventory ($27.4 million vs. $23.9 million) to ensure it aligns with sales velocity and does not indicate obsolescence risks.